← Back to all signals
RESEARCH PAPER ANALYSIS

Mendelian Randomization Analysis of Different Cathepsin Isoforms Associated with Neurodegenerative Diseases.

Mendelian randomization analysis implicates several cathepsin isoforms—most notably cathepsin F—as inversely associated with Parkinson's disease risk, while other isoforms show links to Alzheimer's and epilepsy, but many associations rely on few SNP instruments and European-only data.

PMID41930763
JournalCurrent neurovascular research
Publication Date2026-03-26
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Mendelian randomization analysis implicates several cathepsin isoforms—most notably cathepsin F—as inversely associated with Parkinson's disease risk, while other isoforms show links to Alzheimer's and epilepsy, but many associations rely on few SNP instruments and European-only data.

WHY IT MATTERS

Research significance

Highlights lysosomal cathepsins (especially cathepsin F) as plausible causal contributors and potential biomarker/therapeutic targets for PD, providing a genetically informed rationale for follow-up functional studies and target validation despite requiring replication.

ABSTRACT

Source abstract

INTRODUCTION: Recent studies indicate that cathepsins play an important role in neurodegenerative diseases. However, further exploration is required to determine the association between each isoform of cathepsin and disease. This study aimed to evaluate the potential causal effects of individual cathepsin isoforms on Alzheimer's Disease (AD), Parkinson's Disease (PD), and epilepsy using Mendelian Randomization (MR). METHODS: We used genome-wide association data from the IEU OpenGWAS database. Twosample MR analyses were performed, with Inverse Variance Weighting (IVW) serving as the primary method. Sensitivity analyses, including Cochran's Q test, MR-Egger regression, MRPRESSO, Steiger directionality test, and leave-one-out analysis, were conducted to validate the robustness of the findings. RESULTS: In this study, cathepsins A, B, and F were found to be negatively associated with PD, and a sensitivity analysis was performed to assess the causal association between cathepsin F and PD. The results showed no heterogeneity or pleiotropy. However, the associations for cathepsin A and cathepsin B were each supported by only one SNP, and thus should be interpreted with caution. We also found that cathepsin X is causally related to AD, but this estimate was based on only 2 SNPs, and sensitivity analyses could not be conducted; therefore, the result should be considered exploratory. In addition, we found a positive causal association between Pro-cathepsin H levels, Cathepsin L1 levels, and epilepsy. The sensitivity analyses showed that the results were reliable for these exposures with multiple instrumental variables. Given the limited number of SNPs and the exclusive use of European-ancestry data, these findings should be interpreted cautiously. DISCUSSION: The results showed that there was no heterogeneity or pleiotropy. We also found that cathepsin X is causally related to Alzheimer's disease, but due to the small number of instrumental variables, no sensitivity analysis was performed. In addition, we found a positive causal association between Pro-cathepsin H levels and Cathepsin L1 levels and epilepsy. The sensitivity analyses showed that the results were reliable. CONCLUSION: This study found that different cathepsin isoforms could participate in different neurodegenerative diseases, and have differences in their function, providing preliminary evidence for their potential roles in disease mechanisms.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic